Research location
Hat Yai
Changwat Songkhla, Thailand
Advertisement
Research activity in Hat Yai
Changwat Songkhla, ThailandCureCurrent currently publishes aggregate city-level research activity for this location: 66 trials and 66 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Hat Yai
66 linked trials · page 1 of 2A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)NCT07227597 · 2026-01-29 · 1 site observation
RECRUITING
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 · 2025-12-17 · 1 site observation
RECRUITING
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03 · 1 site observation
RECRUITING
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)NCT07060807 · 2025-07-21 · 1 site observation
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation
RECRUITING
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16 · 1 site observation
RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation
RECRUITING
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944 · 2024-09-20 · 1 site observation
RECRUITING
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]NCT06422143 · 2024-06-10 · 1 site observation
RECRUITING
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung CancerNCT07699328 · 2024-03-26 · 1 site observation
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation
RECRUITING
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16 · 1 site observation
RECRUITING
LA PrEP Impact and Cost-effectiveness (TEAMS)NCT05774548 · 2022-03-15 · 1 site observation
RECRUITING
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCTNCT03648814 · 2018-08-01 · 1 site observation
RECRUITING
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 · 2026-06-22 · 1 site observation
WITHDRAWN
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNCT07128199 · 2025-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)NCT06428396 · 2024-11-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)NCT06430866 · 2024-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721 · 2024-09-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)NCT06305754 · 2024-06-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)NCT05550402 · 2024-02-17 · 1 site observation
UNKNOWN
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)NCT06074588 · 2023-11-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767 · 2023-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)NCT05609968 · 2023-02-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Ultrasound Assessment for Comparison of Gastric Residual Volume After Ingestion of Carbohydrate Drink and Water in Obesity Class II and III Volunteers at Risk of AspirationNCT06941623 · 2023-02-01 · 1 site observation
COMPLETED
Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.NCT06326086 · 2022-08-01 · 1 site observation
UNKNOWN
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27 · 1 site observation
COMPLETED
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)NCT05226598 · 2022-03-24 · 1 site observation
TERMINATED
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · 2022-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsNCT05215340 · 2022-03-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28 · 1 site observation
TERMINATED
The Correlations of FeNO, Blood Eosinophils and Lung Function in Well-controlled AsthmaNCT04454385 · 2020-08-01 · 1 site observation
COMPLETED
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)NCT04221945 · 2020-05-12 · 1 site observation
COMPLETED
As-needed Budesonide/Formoterol Turbuhaler in Stepping Down PeriodNCT04215848 · 2020-04-01 · 1 site observation
COMPLETED
Predicting Intubation of Patients Hospitalised for Acutely Attacked AsthmaNCT04277078 · 2020-02-01 · 1 site observation
COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)NCT03713593 · 2018-12-31 · 1 site observation
COMPLETED
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerNCT03409614 · 2018-03-06 · 1 site observation
COMPLETED
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersNCT03212404 · 2017-09-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of ELIGARD® in Hormone-dependent Prostate Cancer PatientsNCT03035032 · 2017-06-23 · 1 site observation
COMPLETED
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03088540 · 2017-05-29 · 1 site observation
COMPLETED
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022 · 2016-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung CancerNCT02810457 · 2016-09-07 · 1 site observation
COMPLETED
Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down AsthmaNCT02725242 · 2016-03-01 · 1 site observation
COMPLETED
Avelumab in First-line NSCLC (JAVELIN Lung 100)NCT02576574 · 2015-10-29 · 1 site observation
COMPLETED
Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC PatientsNCT02187367 · 2015-05-01 · 1 site observation
TERMINATED
Comparing Nd:YAG Laser and Sequential Double Frequency YAG-Nd:YAG Laser IridotomyNCT02474238 · 2015-05-01 · 1 site observation
COMPLETED
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)NCT02299505 · 2015-04-09 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.